Keywords: combo, roche, xeloda, fares, well, advanced, esophagogastric

Combo with Roche's Xeloda fares well in advanced esophagogastric cancer

Article | 14 January 2008

Print This

Data published in the January 7 issue of the New England Journal of Medicine show that Swiss drug major Roche's oral ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in